Aptahem receives patent protection in South Korea for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection (Notice of Patent Grant) in South Korea for the patent application no 10-2020-7007266 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.
With the approval in South Korea of patent application 10-2020-7007266, the protection of the company’s drug candidate Apta-1 within patent family 2 in South Korea is valid until the end of 2038.
CEO Mikael Lindstam comments
“I am pleased to announce that one of the few remaining patent applications has now been granted patent approval in our patent family 2, which means that we will receive protection for our drug candidate Apta-1 for therapeutic use. South Korea is an important market for pharmaceuticals and especially their interest in new modalities.”
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.